<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39454250</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1360</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of psychosomatic research</Title><ISOAbbreviation>J Psychosom Res</ISOAbbreviation></Journal><ArticleTitle>Dissecting the association between long COVID and depressive symptoms in a nationally representative population from France.</ArticleTitle><Pagination><StartPage>111961</StartPage><MedlinePgn>111961</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychores.2024.111961</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3999(24)00373-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Depressive symptoms may overlap with those of long COVID. This cross-sectional study aims to compare the prevalence of depressive symptoms among individuals infected with SARS-CoV-2 with versus without long COVID and to explore specific associations with each of the nine core symptoms of major depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data regarding age, gender, SARS-CoV-2 infections, current symptoms, their date of onset, impact on daily functioning, and consideration of alternative diagnoses were collected through phone interviews between September and December 2022 in a nationally representative sample of adults aged &#x2265;18. Data on chronic health conditions and depressive symptoms (PHQ-9) were collected online in infected participants with or without long COVID, according to the WHO definition of the post-COVID-19 condition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1247 participants (mean age (SD): 48.3 (14.3) years, 53.3&#xa0;% of women), 12.8&#xa0;% had long COVID and 87.2&#xa0;% experienced SARS-CoV-2 infection at least 3&#xa0;months prior to the survey without long COVID. Participant with long COVID were four-fold more likely to have a PHQ-9 score&#xa0;&#x2265;&#xa0;10 than those without (44.0&#xa0;% versus 11.1&#xa0;%). Three symptoms out of nine were independently associated with long COVID: little interest or pleasure (aOR [95&#xa0;% CI]: 2.01 [1.03-3.92]), feeling tired or having little energy (1.92 [1.10-3.33]), and poor attention/concentration (2.02 [1.03-3.96]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clinicians should screen patients with long COVID for major depression but associations with specific depressive symptoms suggest some clinical overlap. Future studies should consider the course of each depressive symptom separately and focus on those less prone to overlap with symptoms of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tebeka</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sante Publique France), Saint-Maurice, France; Universit&#xe9; de Paris, INSERM UMR1266, Institute of Psychiatry and Neurosciences, Team 1, Paris, France; Department of Psychiatry, AP-HP, Louis Mourier Hospital, F-92700 Colombes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coste</LastName><ForeName>Jo&#xeb;l</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sante Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makovski</LastName><ForeName>Tatjana T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sante Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alleaume</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sante Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delpierre</LastName><ForeName>Cyrille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CERPOP, UMR 1295, Inserm Universit&#xe9; Toulouse III, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallay</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sante Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignon</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Univ Paris-Est-Cr&#xe9;teil (UPEC), AP-HP, H&#xf4;pitaux Universitaires &#xab; H. Mondor &#xbb;, DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, F-94010 Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouraud</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Psychiatrie de l'adulte, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouazana Vedrines</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Psychiatrie de l'adulte, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, F-75004 Paris, France; Universit&#xe9; Paris Cit&#xe9; and Universit&#xe9; Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitron</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, VIFASOM (Vigilance Fatigue Sommeil et Sant&#xe9; Publique), F-75004 Paris, France; Centre du Sommeil et de la Vigilance-Pathologie Professionnelle, APHP, H&#xf4;tel-Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robineau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service Universitaire des Maladies Infectieuses, Centre Hospitalier Gustave Dron, Tourcoing, France; INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, UMR-S 1136, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steichen</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Institut Pierre-Louis d'&#xe9;pid&#xe9;miologie et de sant&#xe9; publique, iPLesp, 75012 Paris, France; Assistance publique-H&#xf4;pitaux de Paris, AP-HP, H&#xf4;pital Tenon, Service de M&#xe9;decine Interne, 75020 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Psychiatrie de l'adulte, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, F-75004 Paris, France; Universit&#xe9; Paris Cit&#xe9; and Universit&#xe9; Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004 Paris, France. Electronic address: cedric.lemogne@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychosom Res</MedlineTA><NlmUniqueID>0376333</NlmUniqueID><ISSNLinking>0022-3999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Sickness behavior</Keyword></KeywordList><CoiStatement>Declaration of competing interest Dr. Lemogne reports non-financial support from Nordic Pharma France, outside the submitted work. The other authors have no interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39454250</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychores.2024.111961</ArticleId><ArticleId IdType="pii">S0022-3999(24)00373-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>